XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENTED INFORMATION
 6 Months Ended
Jun. 30, 2021
SEGMENTED INFORMATION  
NOTE 13 - SEGMENTED INFORMATION

NOTE 13 - SEGMENTED INFORMATION

  

At June 30, 2021, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

 

 

 

BioNexus Gene Lab Corp.

a Wyoming company

 

 

 

 

 

 

 

 

 

 

100% owned

 

 

100% owned

Bionexus Gene Lab  

Sdn. Bhd., 

a Malaysian company

 

 

Chemrex Corporation  

Sdn. Bhd., 

a Malaysian company

 

For the quarter ended June 30, 2021, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

 

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Six months ended June 30, 2021

 

REVENUE

 

$465,470

 

 

$6,075,860

 

 

$-

 

 

$6,541,330

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(358,528)

 

 

(5,132,630)

 

 

-

 

 

(5,491,158)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

106,942

 

 

 

943,230

 

 

 

-

 

 

 

1,050,172

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

3,848

 

 

 

109,068

 

 

 

-

 

 

 

112,916

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(44,128)

 

 

(556,619)

 

 

(80,218)

 

 

(680,265)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(2,303)

 

 

(4,534)

 

 

-

 

 

(6,837)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PROFIT BEFORE TAX

 

 

64,359

 

 

 

491,145

 

 

 

(80,218

)

 

 

475,286

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

(654)

 

 

(107,626)

 

 

-

 

 

(108,280)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET PROFIT

 

$63,705

 

 

$383,519

 

 

$(80,218

) 

 

$367,006

 

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total 

 

 

 

Six months ended June 30, 2020

 

REVENUE

 

$6,541

 

 

$4,167,001

 

 

$-

 

 

$4,173,542

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(30,308)

 

 

(3,328,637)

 

 

-

 

 

(3,358,945)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS (LOSS)/PROFIT

 

 

(23,767)

 

 

838,364

 

 

 

-

 

 

 

814,597

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

7,645

 

 

 

762,718

 

 

 

7

 

 

 

770,370

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(47,254)

 

 

(449,744)

 

 

(48,413)

 

 

(545,411)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,361)

 

 

(3,045)

 

 

-

 

 

(4,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT BEFORE TAX

 

 

(64,737)

 

 

1,148,293

 

 

 

(48,406

)

 

 

1,035,150

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense:

 

 

(1,347)

 

 

0

 

 

 

-

 

 

(1,347)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET (LOSS)/PROFIT

 

$(66,084)

 

$1,148,293

 

 

$(48,406

)

 

$1,033,803

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As Of June 30, 2021 and December 31, 2020

 

 

 

Total Assets

 

 

Total Liabilities

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BGLC & Bionexus

 

$1,378,590

 

 

$1,107,048

 

 

$588,441

 

 

$169,325

 

Chemrex

 

 

8,069,533

 

 

 

9,008,245

 

 

 

2,046,458

 

 

 

3,283,814

 

TOTAL

 

 

9,448,123

 

 

 

10,115,293

 

 

 

2,634,899

 

 

 

3,453,139